Share on StockTwits

CorMedix (NASDAQ:CRMD) released its earnings data on Wednesday. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.13, AnalystRatings.NET reports.

A number of research firms have recently commented on CRMD. Analysts at Zacks downgraded shares of CorMedix to a “neutral” rating in a research note on Monday, July 28th. They now have a $2.20 price target on the stock. Analysts at Roth Capital initiated coverage on shares of CorMedix in a research note on Thursday, July 24th. They set a “buy” rating and a $3.00 price target on the stock.

Shares of CorMedix (NASDAQ:CRMD) opened at 2.09 on Wednesday. CorMedix has a 52-week low of $0.66 and a 52-week high of $3.20. The stock has a 50-day moving average of $1.90 and a 200-day moving average of $1.98. The company’s market cap is $46.0 million.

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.